
    
      This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive
      locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib
      monotherapy.

        -  (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor.

        -  (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
    
  